Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1-Year Longitudinal Study.

Clinical pharmacology and therapeutics - 1 Jul 2025

Piras Marianna, Ranjbar Setareh, Crettol Séverine, Vandenberghe Frederik, Ansermot Nicolas, Grandjean Carole, Pistis Giorgio, Preisig Martin, Curtis Logos, Gamma Franziska, Delessert Didier, Elowe Julien, Plessen Kerstin Jessica, von Gunten Armin, Conus Philippe, Eap Chin Bin

Abstract excerpt

The cytochrome P450 2D6 (CYP2D6) metabolizes around 20% of currently prescribed medications, including the antipsychotic risperidone. Previous studies reported greater odds of switching antipsychotic medication from risperidone among CYP2D6 poor metabolizers (PM) without considering treatment duration up to the switch. Risperidone treatment failure, defined as risperidone treatment duration up to switching...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Drug Substitution

Share to Longitudinal Studies

Share to Risperidone

Share to Time Factors

Share to Treatment Failure

Source

Identifiers

PMID: 40350722
DOI: 10.1002/cpt.3691

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1-Year Longitudinal Study.PMID 40350722Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole.Semantic proximity Read ↗

Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer.Semantic proximity Read ↗

Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.Semantic proximity Read ↗

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.Semantic proximity Read ↗

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.Semantic proximity Read ↗

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studySemantic proximity Read ↗

Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents.Semantic proximity Read ↗

The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.Semantic proximity Read ↗

Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.Semantic proximity Read ↗

Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype.Semantic proximity Read ↗

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.